INTRODUCTION: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. METHODS: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). RESULTS: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q-assessed anxiety, apathy, and nighttime behavior. DISCUSSION: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.

Alzheimer Center Department of Neurology Vrije Universiteit Amsterdam Amsterdam the Netherlands

Department of Neurology Barrow Neurological Institute Phoenix Arizona USA

Department of Neurology Mayo Clinic Rochester Minnesota USA

Department of Neurology University Medical Centre Maribor Maribor Slovenia

Department of Quantitative Health Sciences Mayo Clinic Rochester Minnesota USA

Department of Radiology Mayo Clinic Rochester Minnesota USA

Institute of Sports and Sports Science Karlsruhe Institute of Technology Karlsruhe Germany

International Clinical Research Center St Anne's Hospital Brno Czech Republic

Zobrazit více v PubMed

Banning LCP, Ramakers I, Deckers K, Verhey FRJ, Aalten P. Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer’s disease: A systematic literature review. Neurosci Biobehav Rev. 2019;107:346–359. PubMed

Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–608. PubMed PMC

Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dementia & Geriatric Cognitive Disorders. 2008;25(2):115–126. PubMed

Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Archives of General Psychiatry. 2008;65(10):1193–1198. PubMed PMC

Geda YE, Krell-Roesch J, Sambuchi N, Michel BF. Neuropsychiatric Symptoms and Neuroimaging Biomarkers in Alzheimer Disease: “Which is the Cart and Which is the Horse?”. Am J Geriatr Psychiatry. 2017;25(7):694–696. PubMed

Peters ME, Lyketsos CG. Beyond memory: a focus on the other neuropsychiatric symptoms of dementia. Am J Geriatr Psychiatry. 2015;23(2):115–118. PubMed PMC

Tommasi NS, Gonzalez C, Briggs D, et al. Affective symptoms and regional cerebral tau burden in early-stage Alzheimer’s disease. Int J Geriatr Psychiatry. 2021;36(7):1050–1058. PubMed PMC

Yasuno F, Minami H, Hattori H, Alzheimer’s Disease Neuroimaging I. Relationship between neuropsychiatric symptoms and Alzheimer’s disease pathology: An in vivo positron emission tomography study. Int J Geriatr Psychiatry. 2021;36(4):598–605. PubMed PMC

Tissot C, Therriault J, Pascoal TA, et al. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease. Alzheimers Dement (N Y). 2021;7(1):e12154. PubMed PMC

Miao R, Chen HY, Gill S, et al. Plasma beta-Amyloid in Mild Behavioural Impairment - Neuropsychiatric Symptoms on the Alzheimer’s Continuum. J Geriatr Psychiatry Neurol. 2021:8919887211016068. PubMed

Lee GJ, Lu PH, Hua X, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer’s disease-related regions. Biol Psychiatry. 2012;71(9):814–821. PubMed PMC

Ramakers IH, Verhey FR, Scheltens P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med. 2013;43(5):911–920. PubMed PMC

Nathan PJ, Lim YY, Abbott R, et al. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiol Aging. 2017;53:1–10. PubMed

Reijs BLR, Vos SJB, Soininen H, et al. Association Between Later Life Lifestyle Factors and Alzheimer’s Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. J Alzheimers Dis. 2017;60(4):1387–1395. PubMed

Arnold SE, Xie SX, Leung YY, et al. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry. 2012;2:e65. PubMed PMC

Donovan NJ, Wadsworth LP, Lorius N, et al. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. 2014;22(11):1168–1179. PubMed PMC

Kuo HC, Yen HC, Huang CC, Hsu WC, Wei HJ, Lin CL. Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer’s disease. Int J Neurosci. 2015;125(10):747–754. PubMed

Scaricamazza E, Colonna I, Sancesario GM, et al. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer’s disease patients: a retrospective observational study. Neurol Sci. 2019;40(7):1377–1382. PubMed

Banning LCP, Ramakers I, Kohler S, et al. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer’s Disease Spectrum. Am J Geriatr Psychiatry. 2020; 28(7):735–744. PubMed

Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58–69. PubMed PMC

Rey A L’examen clinique en psychologie. Paris: Presses Universitaires de France; 1964.

Wechsler D Wechsler Memory Scale-Revised. New York: The Psychological Corporation; 1987.

Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.

Lucas JA, Ivnik RJ, Smith GE, et al. Mayo’s Older Americans Normative Studies: category fluency norms. J Clin Exp Neuropsychol. 1998;20(2):194–200. PubMed

Wechsler D Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1981.

Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958;8(3):271–276.

Ivnik R, Malec J, Smith G, et al. Mayo’s Older Americans Normative Studies: WAIS-R, WMS-R, and AVLT norms for ages 56 through 97. Clin Neuropsychol. 1992;6(Supplement):1–104.

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194. PubMed

Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004;256(3):240–246. PubMed

Van Harten AC, Wiste HJ, Weigand SD, et al. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics. Neurology. 2020;95(3):e256–e267. PubMed PMC

Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory-II (BDI-II). San Antonio: Psychology Corporation; 2001.

Beck AT, Steer RA. BAI, Beck Anxiety Inventory: Manual. San Antonio: Psychological Corp. : Harcourt Brace Jovanovich; 1990.

Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. Journal of Neuropsychiatry and Clinical Neurosciences. 2000;12(2):233–239. PubMed

Harrington KD, Lim YY, Gould E, Maruff P. Amyloid-beta and depression in healthy older adults: A systematic review. Aust N Z J Psychiatry. 2015;49(1):36–46. PubMed

Gonzales MM, Insel PS, Nelson C, et al. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. Int J Geriatr Psychiatry. 2018;33(10):1305–1311. PubMed

Showraki A, Murari G, Ismail Z, et al. Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease/Mild Cognitive Impairment: A Systematic Review. J Alzheimers Dis. 2019;71(2):477–501. PubMed

Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature. 2008;451(7179):720–724. PubMed PMC

Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005–1007. PubMed PMC

Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409–421. PubMed

Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch Neurol. 1995;52(1):81–88. PubMed

Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain. 2006;129(Pt 11):3035–3041. PubMed

Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019;51(5):1–10. PubMed PMC

Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;3:CD010803. PubMed PMC

Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470–1481. PubMed PMC

Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O, Geneva Task Force for the Roadmap of Alzheimer’s B. Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:196–213. PubMed

Wang MJ, Yi S, Han JY, et al. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer’s Disease with Updated Protocols. J Alzheimers Dis. 2016;52(4):1403–1413. PubMed

Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1–42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011;68(9):1137–1144. PubMed PMC

Krell-Roesch J, Lowe VJ, Neureiter J, et al. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. Int Psychogeriatr. 2018;30(2):245–251. PubMed PMC

Ismail Z, Aguera-Ortiz L, Brodaty H, et al. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. J Alzheimers Dis. 2017;56(3):929–938. PubMed PMC

Lussier FZ, Pascoal TA, Chamoun M, et al. Mild behavioral impairment is associated with beta-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement. 2020;16(1):192–199. PubMed PMC

Johansson M, Stomrud E, Insel PS, et al. Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease. Transl Psychiatry. 2021;11(1):76. PubMed PMC